Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Manca, Andrea
and
Davies, Linda
1999.
An Economic Analysis of the Management of Alzheimer's Disease in the United Kingdom.
British Menopause Society Journal,
Vol. 5,
Issue. 4,
p.
167.
Kirchner, Vincent
Elloy, Marianne D
Silver, Louise E
and
Kelly, Cornelius A
2000.
Dementia: the cost of care for behaviourally disturbed patients living in the community.
International Journal of Geriatric Psychiatry,
Vol. 15,
Issue. 11,
p.
1000.
Andrew, Toby
Moriarty, Jo
Levin, Enid
and
Webb, Sarah
2000.
Outcome of referral to social services departments for people with cognitive impairment.
International Journal of Geriatric Psychiatry,
Vol. 15,
Issue. 5,
p.
406.
Kendall, Jeremy
and
Knapp, Martin
2001.
Voluntary Organisations and Social Policy in Britain.
p.
108.
Kavanagh, Shane
and
Knapp, Martin
2002.
Costs and cognitive disability: modelling the underlying associations.
British Journal of Psychiatry,
Vol. 180,
Issue. 2,
p.
120.
Wolstenholme, Jane L.
Fenn, Paul
Gray, Alastair M.
Keene, Janet
Jacoby, Robin
and
HOPE, TONY
2002.
Estimating the relationship between disease progression and cost of care in dementia.
British Journal of Psychiatry,
Vol. 181,
Issue. 1,
p.
36.
Jönsson, Linus
2003.
Pharmacoeconomics of cholinesterase inhibitors in the treatment of Alzheimer’s disease.
PharmacoEconomics,
Vol. 21,
Issue. 14,
p.
1025.
Bloom, Bernard S.
de Pouvourville, Nathalie
and
Straus, Walter L.
2003.
Cost of Illness of Alzheimer's Disease: How Useful Are Current Estimates?.
The Gerontologist,
Vol. 43,
Issue. 2,
p.
158.
Leber, Paul
Millson, David
Jolley, David
Ward, Harry
Qizilbash, Nawab
and
Schneider, Lon S.
2003.
Evidence‐based Dementia Practice.
p.
376.
Ward, A.
Caro, J. J.
Getsios, D.
Ishak, K.
O'Brien, J.
and
Bullock, R.
2003.
Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK.
International Journal of Geriatric Psychiatry,
Vol. 18,
Issue. 8,
p.
740.
López-Pousa, Secundino
Garre-Olmo, Josep
Turon-Estrada, Antoni
Hernández, Francisco
Expósito, Inmaculada
Lozano-Gallego, Manoli
Hernández-Ferrándiz, Marta
Gelada-Batlle, Esther
Pericot-Nierga, Imma
and
Vilalta-Franch, Joan
2004.
Análisis de los costes de la enfermedad de Alzheimer en función del deterioro cognitivo y funcional.
Medicina Clínica,
Vol. 122,
Issue. 20,
p.
767.
Bullock, Roger
2004.
The Needs of the Caregiver in the Long-Term Treatment of Alzheimer Disease.
Alzheimer Disease & Associated Disorders,
Vol. 18,
Issue. ,
p.
S17.
Knapp, Martin
Thorgrimsen, Lene
Patel, Anita
Spector, Aimee
Hallam, Angela
Woods, Bob
and
Orrell, Martin
2006.
Cognitive stimulation therapy for people with dementia: cost-effectiveness analysis.
British Journal of Psychiatry,
Vol. 188,
Issue. 6,
p.
574.
Bosanquet, Nick
and
Yeates, Andrew
2006.
Modelling the Cost Effectiveness of Cholinesterase Inhibitors in the Management of Mild to Moderately Severe Alzheimer???s Disease.
PharmacoEconomics,
Vol. 24,
Issue. 6,
p.
623.
Kirby, Joanna
Green, Colin
Loveman, Emma
Clegg, Andrew
Picot, Joanna
Takeda, Andrea
and
Payne, Elizabeth
2006.
A Systematic Review of the Clinical and Cost-Effectiveness of Memantine in Patients with Moderately Severe to Severe Alzheimer???s Disease.
Drugs & Aging,
Vol. 23,
Issue. 3,
p.
227.
Gammanpila, Udaya P
Burns, Alistair
Heller, Richard F
and
Purandare, Nitin
2007.
What are the benefits of cognitive enhancers for Alzheimer's Disease: use of Population Impact Measures.
BMC Geriatrics,
Vol. 7,
Issue. 1,
Quentin, W.
Riedel‐Heller, S. G.
Luppa, M.
Rudolph, A.
and
König, H.‐H.
2010.
Cost‐of‐illness studies of dementia: a systematic review focusing on stage dependency of costs.
Acta Psychiatrica Scandinavica,
Vol. 121,
Issue. 4,
p.
243.
Mauskopf, J.
Racketa, J.
and
Sherrill, E.
2010.
Alzheimer's disease: The strength of association of costs with different measures of disease severity.
The Journal of nutrition, health and aging,
Vol. 14,
Issue. 8,
p.
655.
eLetters
No eLetters have been published for this article.